ABOUT US

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

Leveraging data from next-generation sequencing and regulatory networks (DNA-protein & protein-protein), the platform takes a systematic big-data approach to identify the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.

The Company is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating and licensing novel IP related to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.

Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology platform via a model that includes development and out-license of internally developed cell therapy assets, development and license of novel cell conversion IP, and the formation of joint-ventures to exploit the platform and/or novel cell conversion IP in non-core areas.

OUR HISTORY

FANTOM 5 Launch

RIKEN scientists  launch international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.

2009

Mogrify Development

Julian Gough and Owen Rackham begin the V1 platform development using the unpublished FANTOM 5 consortium data.

2011

Mogrify Validation

Collaboration with co-founder Jose Polo to test cell conversions begins and three new conversions are validated with the V1 platform in just several months.

2012

Foundation Patent

Julian Gough, Owen Rackham, Jose Polo file a PCT patent for the V1 platform and over 30 direct cell conversions.

2015

Nature Genetics

V1 platform and cell conversion results published in Nature Genetics journal featuring on the front page.

2016

Platform Development

Mogrify Ltd incorporated with pre-seed and grant funding to begin the industrial development and application of the V1 platform.

2016 to 2018

Growth Phase

$3.7M seed capital raised, appoints Dr. Darrin M. Disley, OBE as CEO, launch of Mogrify V2 and Epimogrify V1 platforms, hiring up to 40 scientists and raising significant Series A funding. Dr. Jane Osbourn, OBE appointed as Chair.

2019

Transforming Cell Therapy (1)
(a) Differential gene expression levels are identified by comparing RNA sequencing data, while using the FANTOM5 database as background.
Transforming Cell Therapy (2)
(b) All human transcription factors are ranked according to their effect on the identified differential gene expression using both direct (DNA-protein interactions, MARA database) and indirect effects (protein-protein interactions, STRING database).
Transforming Cell Therapy (3)
(c) The optimal combination of transcription factors is identified in order to maximize the differential gene expression while minimizing the overlap in effects.
shape imgshape imgshape img
triangle img

OUR TECHNOLOGY

Mogrify has developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo), needed to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell- or even a progenitor cell-state. Mogrify will apply this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development and manufacturing, which is estimated to represent a $30 billion USD market opportunity and is rapidly growing (CAGR +30%).

Multiple patents pending.

triangle img
triangle

PARTNERING & INVESTING

Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, cell therapies, biomanufacturing and research tools to develop cell conversions from proof-of-concept to commercial products with impact in their respective market sectors. Once commercially viable cell conversions have been developed, Mogrify will look to license the intellectual property or go to market as a joint venture.

triangle

OUR CURRENT INVESTORS

shape imgshape img
triangle

CONTACT US

25 Cambridge Science Park
Milton Road
Cambridge
CB4 0FW
UK
triangle